Zobrazeno 1 - 10
of 281
pro vyhledávání: '"Jonathan R Strosberg"'
Publikováno v:
Canadian Journal of Gastroenterology, Vol 21, Iss 2, Pp 113-115 (2007)
A 43-year-old man with a history of metastatic carcinoid disease is presented. The patient had symptoms of chronic intermittent abdominal pain two years after undergoing a wireless capsule endoscopy procedure. Radiological examinations revealed a ret
Externí odkaz:
https://doaj.org/article/44f6465b08444e258afff702d2572d5b
Autor:
Zhiwen Xiao, Huaxiang Xu, Jonathan R. Strosberg, Renquan Lu, Xinzhe Zhu, Shengming Deng, Lei Ding, Quanxing Ni, Andrew L. Warshaw, Xianjun Yu, Guopei Luo
Publikováno v:
International Journal of Cancer. 153:164-172
Autor:
Pamela L. Kunz, Noah T. Graham, Paul J. Catalano, Halla S. Nimeiri, George A. Fisher, Teri A. Longacre, Carlos J. Suarez, Brock A. Martin, James C. Yao, Matthew H. Kulke, Andrew E. Hendifar, James C. Shanks, Manisha H. Shah, Mark M. Zalupski, Edmond L. Schmulbach, Diane L. Reidy-Lagunes, Jonathan R. Strosberg, Peter J. O'Dwyer, Al B. Benson
Publikováno v:
Journal of Clinical Oncology. 41:1359-1369
PURPOSE Patients with advanced pancreatic neuroendocrine tumors (NETs) have few treatment options that yield objective responses. Retrospective and small prospective studies suggest that capecitabine and temozolomide are associated with high response
Autor:
Moozhan Nikpanah, Faraz Farhadi, Michael A. Morris, Naris Nilubol, Chuong D. Hoang, Nitin Roper, Jonathan M. Hernandez, Clara Chen, Emily Bergsland, Bradford J. Wood, Corina Millo, Jonathan R. Strosberg, Elizabeth C. Jones, Ashkan A. Malayeri, Babak Saboury, Jaydira Del Rivero
Publikováno v:
Clinical and Translational Imaging. 10:285-299
Autor:
Arnaud Demange, Hugo Duarte, Jonathan R. Strosberg, Andrew Eugene Hendifar, James C. Yao, Philippe Ruszniewski, Germo Gericke, Marianne Pavel, Martyn Caplin, Eric P. Krenning, Sakir Mutevelic, Edward M. Wolin, Mariani Maurizio F, Erik Mittra, Pamela L. Kunz, Enrique Grande, Ettore Seregni, Lisa Bodei, Amy Bartalotta, Eric Van Cutsem
Publikováno v:
The Lancet Oncology, 22(12), 1752-1763. Lancet Publishing Group
Summary Background The primary analysis of the phase 3 NETTER-1 trial showed significant improvement in progression-free survival with 177Lu-Dotatate plus long-acting octreotide versus high-dose long-acting octreotide alone in patients with advanced
Publikováno v:
The Lancet Oncology. 24:121-122
Publikováno v:
Digestive Disease Interventions. :103-112
Transarterial radioembolization (TARE) using β-emitting yttrium-90 microspheres has been used for decades in patients with liver-dominant unresectable metastatic neuroendocrine tumors (mNETs). TARE is one of the embolotherapies supported by the Nati
Autor:
James Yu, Estrella Carballido, Richard D. Kim, Maria Elena Martinez, Iman Imanirad, Michael J. Schell, Jun-Min Zhou, Elaine Tan, Dae-Won Kim, Rutika Mehta, Jonathan R. Strosberg
Publikováno v:
Br J Cancer
BACKGROUND: MMR proficient (pMMR) colorectal cancer (CRC) is usually unresponsive to immunotherapy. Recent data suggest that ibrutinib may enhance the anti-tumour activity of anti-PD-1 immunotherapy. In this study, we evaluated the safety and efficac
Autor:
Emily K. Bergsland, Jonathan R. Strosberg, Manisha H. Shah, Hilary Chan, Matthew H. Kulke, Michael A. Choti, Al B. Benson, Mark Bloomston, James C. Yao, Li Zhang, Eric K. Nakakura, Katherine Van Loon
Publikováno v:
Pancreas, vol 50, iss 4
Pancreas
Pancreas
Objective Current National Comprehensive Cancer Network guidelines for gastroenteropancreatic neuroendocrine tumors (GEPNETs) recommend complete (R0) surgical resection of the primary tumor and metastases, if feasible. However, large multicenter stud
Autor:
Narges K. Tafreshi, Haitao Ji, Robert W. Engelman, Jordan N Reff, Zhen Wang, Thaddeus J. Wadas, Alberto Chiappori, Christopher J. Tichacek, David L. Morse, Ghassan El-Haddad, Darpan N. Pandya, Mikalai M. Budzevich, David Boulware, Jonathan R. Strosberg
Publikováno v:
European Journal of Nuclear Medicine and Molecular Imaging. 48:3408-3421
There is significant interest in the development of targeted alpha-particle therapies (TATs) for treatment of solid tumors. The metal chelator-peptide conjugate, DOTA-TATE, loaded with the β-particle emitting radionuclide 177Lu ([177Lu]Lu-DOTA-TATE)